Osteogenic regenerative scaffold matrix composition
US9642942B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 16, 2015 |
| Grant date | May 9, 2017 |
| Priority date | — |
| Expiry date | Jul 16, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2430/02
- WIPO fieldMedical technology
- WIPO sectorInstruments
Abstract
The implantable scaffold matrix composition for osteogenic regeneration has a biodegradable polymer material selected from the group consisting of one or more of polylactic acid, polyglycolic acid, or polycaprolactone, or any combination thereof to provide a time release delivery of an osteogenic effect and further has a pharmaceutical composition selected from the group consisting of one or more of ibuprofen, non-steroidal anti-inflammatory drugs (NSAIDS), acetaminophen, or naproxen sodium or any combination thereof and wherein the implantable composition has a primary and a secondary time release. The primary time release being one of the polymer compositions; each time release extending occurring between 0 days and 19 days, both not being at 0 days. In a preferred composition, the scaffold has an organic material for inhibiting osteoclast selected from a group consisting of one or more of Galardin, Decorin, Actinonin, Marimastat, Batimastat, and phosphodiesterase type 4 or any combination of osteoclast inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.